R&D News | pharmaphorum

News

SparingVision to buy GAMUT and potential Luxturna eye gene t...

French genomic medicines firm SparingVision has agreed to buy GAMUT Therapeutics, a biotech specialising in gene therapies for inherited eye diseases such as retinitis pigmentosa (RP) that

News

UK Vaccine Taskforce head lifts lid on Novavax deal

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce.&nbs

News

Activist investor Elliott builds stake in GSK after fresh tr...

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to t

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Magic mushroom compound matches antidepressant in clinical t...

The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.

News

Risk of brain clots higher with COVID than vaccine, study su...

A study has suggested that the risk of getting a serious brain clot is eight to 10 times higher in people with COVID-19 than those who get a vaccine.

News

Evrysdi has 'real world impact' on lives of babies with seve...

Roche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal muscular atrophy (SMA), the rare muscle wasting disease that is often fatal in ba

SparingVision to buy GAMUT and potential Luxturna eye gene t...

UK Vaccine Taskforce head lifts lid on Novavax deal

Activist investor Elliott builds stake in GSK after fresh tr...

Magic mushroom compound matches antidepressant in clinical t...

Risk of brain clots higher with COVID than vaccine, study su...

Evrysdi has 'real world impact' on lives of babies with seve...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks